{"disease":{"id":"tn-er-pr-her2-breast-cancer","name":"tn er pr her2 breast cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04585750","title":"The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"PMV Pharmaceuticals, Inc","has_results":false},{"nct_id":"NCT03981705","title":"Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":8,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}